Literature DB >> 22005942

Therapeutic modalities in diabetic nephropathy: standard and emerging approaches.

Emaad M Abdel-Rahman1, Lawand Saadulla, W Brian Reeves, Alaa S Awad.   

Abstract

Diabetes mellitus is the leading cause of end stage renal disease and is responsible for more than 40% of all cases in the United States. Current therapy directed at delaying the progression of diabetic nephropathy includes intensive glycemic and optimal blood pressure control, proteinuria/albuminuria reduction, interruption of the renin-angiotensin-aldosterone system through the use of angiotensin converting enzyme inhibitors and angiotensin type-1 receptor blockers, along with dietary modification and cholesterol lowering agents. However, the renal protection provided by these therapeutic modalities is incomplete. More effective approaches are urgently needed. This review highlights the available standard therapeutic approaches to manage progressive diabetic nephropathy, including markers for early diagnosis of diabetic nephropathy. Furthermore, we will discuss emerging strategies such as PPAR-gamma agonists, Endothelin blockers, vitamin D activation and inflammation modulation. Finally, we will summarize the recommendations of these interventions for the primary care practitioner.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22005942      PMCID: PMC3304033          DOI: 10.1007/s11606-011-1912-5

Source DB:  PubMed          Journal:  J Gen Intern Med        ISSN: 0884-8734            Impact factor:   5.128


  200 in total

1.  Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study.

Authors:  I M Stratton; A I Adler; H A Neil; D R Matthews; S E Manley; C A Cull; D Hadden; R C Turner; R R Holman
Journal:  BMJ       Date:  2000-08-12

2.  Renoprotective effects of angiotensin II receptor blockade in type 1 diabetic patients with diabetic nephropathy.

Authors:  S Andersen; L Tarnow; P Rossing; B V Hansen; H H Parving
Journal:  Kidney Int       Date:  2000-02       Impact factor: 10.612

3.  Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial.

Authors:  Dick de Zeeuw; Rajiv Agarwal; Michael Amdahl; Paul Audhya; Daniel Coyne; Tushar Garimella; Hans-Henrik Parving; Yili Pritchett; Giuseppe Remuzzi; Eberhard Ritz; Dennis Andress
Journal:  Lancet       Date:  2010-11-06       Impact factor: 79.321

4.  Regression of microalbuminuria in type 1 diabetes is associated with lower levels of urinary tubular injury biomarkers, kidney injury molecule-1, and N-acetyl-β-D-glucosaminidase.

Authors:  Vishal S Vaidya; Monika A Niewczas; Linda H Ficociello; Amanda C Johnson; Fitz B Collings; James H Warram; Andrzej S Krolewski; Joseph V Bonventre
Journal:  Kidney Int       Date:  2010-10-27       Impact factor: 10.612

5.  Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy.

Authors:  John M Lachin; Saul Genuth; Patricia Cleary; Matthew D Davis; David M Nathan
Journal:  N Engl J Med       Date:  2000-02-10       Impact factor: 91.245

6.  Bardoxolone methyl and kidney function in CKD with type 2 diabetes.

Authors:  Pablo E Pergola; Philip Raskin; Robert D Toto; Colin J Meyer; J Warren Huff; Eric B Grossman; Melissa Krauth; Stacey Ruiz; Paul Audhya; Heidi Christ-Schmidt; Janet Wittes; David G Warnock
Journal:  N Engl J Med       Date:  2011-06-24       Impact factor: 91.245

7.  Effect of bardoxolone methyl on kidney function in patients with T2D and Stage 3b-4 CKD.

Authors:  Pablo E Pergola; Melissa Krauth; J Warren Huff; Deborah A Ferguson; Stacey Ruiz; Colin J Meyer; David G Warnock
Journal:  Am J Nephrol       Date:  2011-04-21       Impact factor: 3.754

8.  Thiazolidinedione compounds ameliorate glomerular dysfunction independent of their insulin-sensitizing action in diabetic rats.

Authors:  K Isshiki; M Haneda; D Koya; S Maeda; T Sugimoto; R Kikkawa
Journal:  Diabetes       Date:  2000-06       Impact factor: 9.461

9.  Effect of blood pressure control on diabetic microvascular complications in patients with hypertension and type 2 diabetes.

Authors:  R O Estacio; B W Jeffers; N Gifford; R W Schrier
Journal:  Diabetes Care       Date:  2000-04       Impact factor: 19.112

10.  Diabetes, hypertension, and outcome studies: overview 2010.

Authors:  Peter M Nilsson; Jan Cederholm
Journal:  Diabetes Care       Date:  2011-05       Impact factor: 19.112

View more
  18 in total

1.  Arginase inhibition: a new treatment for preventing progression of established diabetic nephropathy.

Authors:  Hanning You; Ting Gao; Timothy K Cooper; Sidney M Morris; Alaa S Awad
Journal:  Am J Physiol Renal Physiol       Date:  2015-06-03

2.  Distinct roles of arginases 1 and 2 in diabetic nephropathy.

Authors:  Sidney M Morris; Hanning You; Ting Gao; Jean Vacher; Timothy K Cooper; Alaa S Awad
Journal:  Am J Physiol Renal Physiol       Date:  2017-04-26

3.  Therapeutic Modalities in Diabetic Nephropathy: Future Approaches.

Authors:  William Brian Reeves; Bishal B Rawal; Emaad M Abdel-Rahman; Alaa S Awad
Journal:  Open J Nephrol       Date:  2012-06-25

4.  Protective role of small pigment epithelium-derived factor (PEDF) peptide in diabetic renal injury.

Authors:  Alaa S Awad; Ting Gao; Anzor Gvritishvili; Hanning You; Yanling Liu; Timothy K Cooper; W Brian Reeves; Joyce Tombran-Tink
Journal:  Am J Physiol Renal Physiol       Date:  2013-07-24

Review 5.  Stem cells as a therapeutic approach to chronic kidney diseases.

Authors:  Sargis Sedrakyan; Susanne Angelow; Roger E De Filippo; Laura Perin
Journal:  Curr Urol Rep       Date:  2012-02       Impact factor: 3.092

6.  Enhancing kidney DDAH-1 expression by adenovirus delivery reduces ADMA and ameliorates diabetic nephropathy.

Authors:  Michael D Wetzel; Ting Gao; Kristen Stanley; Timothy K Cooper; Sidney M Morris; Alaa S Awad
Journal:  Am J Physiol Renal Physiol       Date:  2020-01-06

7.  Anthocyanins inhibit high-glucose-induced cholesterol accumulation and inflammation by activating LXRα pathway in HK-2 cells.

Authors:  Chunyang Du; Yonghong Shi; Yunzhuo Ren; Haijiang Wu; Fang Yao; Jinying Wei; Ming Wu; Yanjuan Hou; Huijun Duan
Journal:  Drug Des Devel Ther       Date:  2015-09-04       Impact factor: 4.162

8.  Macrophage-derived tumor necrosis factor-α mediates diabetic renal injury.

Authors:  Alaa S Awad; Hanning You; Ting Gao; Timothy K Cooper; Sergei A Nedospasov; Jean Vacher; Patrick F Wilkinson; Francis X Farrell; W Brian Reeves
Journal:  Kidney Int       Date:  2015-06-10       Impact factor: 10.612

9.  Delayed Treatment with a Small Pigment Epithelium Derived Factor (PEDF) Peptide Prevents the Progression of Diabetic Renal Injury.

Authors:  Alaa S Awad; Hanning You; Ting Gao; Anzor Gvritishvili; Timothy K Cooper; Joyce Tombran-Tink
Journal:  PLoS One       Date:  2015-07-24       Impact factor: 3.240

10.  Tripterygium Glycosides Tablet Ameliorates Renal Tubulointerstitial Fibrosis via the Toll-Like Receptor 4/Nuclear Factor Kappa B Signaling Pathway in High-Fat Diet Fed and Streptozotocin-Induced Diabetic Rats.

Authors:  Ze-Jun Ma; Xiao-Na Zhang; Li Li; Wei Yang; Shan-Shan Wang; Xin Guo; Pei Sun; Li-Ming Chen
Journal:  J Diabetes Res       Date:  2015-08-12       Impact factor: 4.011

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.